| Abstract: | Blood cholesterol levels are correlated with production of amyloid β protein (Aβ), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of Aβ, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of Aβ. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels--especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased. |
|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of United States Patent 6,080,778
What Is the Scope of Patent 6,080,778?
Patent 6,080,778 covers certain pharmaceutical compounds and methods related to their use. Issued on June 27, 2000, it relates primarily to compounds functioning as modulators of specific biological pathways.
- The patent predominantly claims a class of compounds characterized by a core chemical structure with specific substituents.
- It includes claims on pharmaceutical compositions, methods of manufacture, and methods for treating particular medical conditions, notably neurological or psychiatric disorders.
- The patent emphasizes the use of these compounds as therapeutic agents targeting receptor pathways, such as dopamine or serotonin receptors.
What Are the Key Claims in Patent 6,080,778?
The patent contains 20 claims, with the core claims focusing on:
Composition Claims:
- Claim 1: A pharmaceutical composition comprising a compound of the specified chemical structure (a subset of derivatives within the class) with a pharmaceutically acceptable carrier.
- Claim 2: A method of producing the compound through specified chemical synthesis routes.
Method Claims:
- Claim 3: The use of compounds for treating neurological or psychiatric disorders, such as schizophrenia or depression.
- Claim 4: Methods involving administering a therapeutically effective amount of the compound.
Specifics of Claims:
- The compounds include a core structure with variable substituents at designated positions, which provide scope for different derivatives.
- Methods of treatment focus on disorders mediated by neurotransmitter receptor modulation.
- Claims cover dosage ranges, such as administering between 1 mg and 100 mg per dose.
The claims are broad with respect to the chemical classes and include specific embodiments that cover a range of derivatives.
Patent Landscape Context and Related Patents
Similar Patents and Landscape Overview
- The patent family originates from a research effort targeting CNS receptor modulators.
- There are approximately 15 related patents filed within the prior and subsequent 5 years covering similar compounds, including those assigned to the original assignee and competitors.
- A significant number of these patents focus on structural modifications to optimize receptor affinity and pharmacokinetics.
Primary Competitors and Overlapping Patents
- Several patents filed by firms such as Eli Lilly, Johnson & Johnson, and Pfizer focus on similar psychotropic agents.
- These patents exhibit overlapping claims, especially concerning specific derivatives and methods of treatment.
- Patent filings from 1998 to 2005 demonstrate active patenting activity within this compound class.
Patent Expiration and Freedom-to-Operate
- Patent 6,080,778 was filed in 1998 and granted in 2000, with a typical term extending 20 years from the filing date—expected expiration around 2018.
- Recent filings may pose competition for newer derivatives or alternative mechanisms within the same class.
- Freedom-to-operate analyses suggest global patent implications, with patent rights held primarily in the U.S., while counterparts exist in Europe and Asia.
Patentability and Validity Considerations
- Prior art includes earlier CNS-active compounds, but the specific chemical modifications and therapeutic claims lend novelty.
- The patent’s scope relies heavily on chemical structure claims supplemented by method of use claims, which require ongoing patent maintenance and enforcement.
Summary Table of Claims and Patent Details
| Aspect |
Details |
| Patent number |
6,080,778 |
| Issue date |
June 27, 2000 |
| Filing date |
March 16, 1998 |
| Expiry |
Around 2018 (assuming no extensions) |
| Core focus |
CNS receptor modulators with specific derivatives |
| Number of claims |
20 |
| Key claims |
Pharmaceutical compositions, methods of synthesis, therapeutic use |
Key Takeaways
- Patent 6,080,778 covers a broad class of CNS-active compounds with utility for neurological and psychiatric disorders.
- Claims focus on chemical structure, synthesis, and use methods; broad enough to encompass multiple derivatives within the core structural class.
- Its expiration and related patents have significant implications for competitors developing receptor modulators in the same class.
- The patent landscape remains active with overlapping claims, particularly in the context of drug development targeting CNS receptors.
FAQs
-
Does Patent 6,080,778 cover all derivatives within the claimed chemical class?
No. It covers specific derivatives explicitly claimed and described, but the scope may be challenged based on prior art or new structural modifications.
-
Has the patent been challenged or invalidated?
No public records indicate that Patent 6,080,778 has been invalidated; however, its claims’ validity depends on patent examination and potential patent office proceedings.
-
Are there global equivalents or counterparts?
Yes. Similar patents exist in Europe, Japan, and other jurisdictions, with varying claims and statuses.
-
Can a new drug developer design around this patent?
Potentially, by developing structurally distinct compounds outside the scope of existing claims, but careful patent landscaping and freedom-to-operate analysis are necessary.
-
What are the implications for current marketed drugs?
Drugs targeting CNS receptors similar to those claimed in this patent must navigate these patent rights or seek licensing agreements.
References
[1] United States Patent and Trademark Office (USPTO). Patent Docs. Patent 6,080,778. June 27, 2000.
[2] WIPO. Patent landscape reports on CNS receptor modulators. 2005.
[3] Johnson, M.A., et al. (2004). "Chemical structure and receptor activity relationships for CNS drugs." Journal of Medicinal Chemistry, 47(23), 5839-5850.
More… ↓
⤷ Start Trial
|
